Found: 4
Select item for more details and to access through your institution.
Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-022-01418-8
- By:
- Publication type:
- Article
Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 4, p. 484, doi. 10.1111/head.14476
- By:
- Publication type:
- Article
Early clinical experience with eptinezumab: results of a retrospective observational study of patient response in the United States.
- Published in:
- BMC Neurology, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12883-023-03204-8
- By:
- Publication type:
- Article
Improving to Four or Fewer Monthly Headache Days Per Month Provides a Clinically Meaningful Therapeutic Target for Patients with Chronic Migraine.
- Published in:
- Pain & Therapy, 2023, v. 12, n. 5, p. 1179, doi. 10.1007/s40122-023-00525-x
- By:
- Publication type:
- Article